title: Outcomes after adult isolated small bowel transplantation: experience from a single European centre.
abstract: BACKGROUND
  Adult isolated small bowel transplantation is considered the standard treatment for patients with life-threatening parenteral nutrition-related complications. Here, we report a 3-year experience in a single European centre between December 2000 and December 2003.
  
  
  OBJECTIVE
  To evaluate and discuss pre-transplant and post-transplant factors that influenced survival rates in our series.
  
  
  METHODS
  Fourteen patients, with a mean parenteral nutrition course of 27 months, were transplanted. In eight cases they had not experienced any major complication from parenteral nutrition.
  
  
  METHODS
  We described pre-transplant evaluation and inclusion criteria, surgical technique and clinical management after transplant. Immunosuppressive therapy was based on induction drugs and Tacrolimus. We reported survival rates, major complications and rejection events.
  
  
  RESULTS
  One-year actuarial survival rate was of 92.3% with a mean 21-month follow-up (range 3-36 months). We had no intraoperative deaths. One patient (7.2%) died of sepsis following cytomegalovirus enteritis. One patient underwent graftectomy (7.2%) for intractable severe acute rejection. One-year actuarial graft survival rate of 85.1%. One patient (7.2%) affected by post-transplant lymphoproliferative disease is alive and disease-free after 8 months.
  
  
  CONCLUSIONS
  We believe candidate selection, induction therapy, donor selection and short ischemia time play an important role in survival after small bowel transplantation.
authors.affiliation: Liver and Multivisceral Transplant Centre, University of Modena and Reggio Emilia, Policlinico of Modena-via del Pozzo 71, 41100 Modena, Italy. f.diben@virgilio.it
authors.forename: F
authors.initials: F
authors.lastname: Di Benedetto
authors.forename: A
authors.initials: A
authors.lastname: Lauro
authors.forename: M
authors.initials: M
authors.lastname: Masetti
authors.forename: N
authors.initials: N
authors.lastname: Cautero
authors.forename: C
authors.initials: C
authors.lastname: Quintini
authors.forename: A
authors.initials: A
authors.lastname: Dazzi
authors.forename: N
authors.initials: N
authors.lastname: De Ruvo
authors.forename: T Diago
authors.initials: TD
authors.lastname: Uso
authors.forename: B
authors.initials: B
authors.lastname: Begliomini
authors.forename: A
authors.initials: A
authors.lastname: Siniscalchi
authors.forename: A
authors.initials: A
authors.lastname: Bagni
authors.forename: M
authors.initials: M
authors.lastname: Codeluppi
authors.forename: G
authors.initials: G
authors.lastname: Ramacciato
authors.forename: E
authors.initials: E
authors.lastname: Villa
authors.forename: A D
authors.initials: AD
authors.lastname: Pinna
mesh_terms: D000328:Adult; D013505:Digestive System Surgical Procedures / Q000379:methods; D005060:Europe; D005260:Female; D005500:Follow-Up Studies; D006084:Graft Rejection; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007413:Intestinal Mucosa / Q000187:drug effects / Q000473:pathology; D007421:Intestine, Small / Q000473:pathology / Q000637:transplantation*; D008297:Male; D008875:Middle Aged; D011182:Postoperative Care; D016019:Survival Analysis; D015996:Survival Rate; D016378:Tissue Transplantation / Q000009:adverse effects / Q000401:mortality*; D016896:Treatment Outcome
chemical_list: D007166:Immunosuppressive Agents